- Home
- IHD vs AVTX Comparison
IHD vs AVTX Comparison
Compare IHD & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHD
- AVTX
- Stock Information
- Founded
- IHD 2011
- AVTX 2011
- Country
- IHD United States
- AVTX United States
- Employees
- IHD N/A
- AVTX N/A
- Industry
- IHD Investment Managers
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IHD Finance
- AVTX Health Care
- Exchange
- IHD Nasdaq
- AVTX Nasdaq
- Market Cap
- IHD 108.0M
- AVTX 138.8M
- IPO Year
- IHD N/A
- AVTX 2015
- Fundamental
- Price
- IHD $6.15
- AVTX $11.33
- Analyst Decision
- IHD
- AVTX Strong Buy
- Analyst Count
- IHD 0
- AVTX 9
- Target Price
- IHD N/A
- AVTX $30.14
- AVG Volume (30 Days)
- IHD 27.7K
- AVTX 188.1K
- Earning Date
- IHD 01-01-0001
- AVTX 11-06-2025
- Dividend Yield
- IHD 10.32%
- AVTX N/A
- EPS Growth
- IHD N/A
- AVTX N/A
- EPS
- IHD N/A
- AVTX N/A
- Revenue
- IHD N/A
- AVTX $441,000.00
- Revenue This Year
- IHD N/A
- AVTX N/A
- Revenue Next Year
- IHD N/A
- AVTX N/A
- P/E Ratio
- IHD N/A
- AVTX N/A
- Revenue Growth
- IHD N/A
- AVTX N/A
- 52 Week Low
- IHD $4.49
- AVTX $3.39
- 52 Week High
- IHD $5.47
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- IHD 66.36
- AVTX 62.61
- Support Level
- IHD $6.05
- AVTX $9.54
- Resistance Level
- IHD $5.95
- AVTX $12.41
- Average True Range (ATR)
- IHD 0.06
- AVTX 1.05
- MACD
- IHD 0.01
- AVTX -0.10
- Stochastic Oscillator
- IHD 97.94
- AVTX 71.28
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).